An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. - Wikidata - wikimedia - TriplyDB

An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity.

An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity.

http://www.wikidata.org/entity/Q42906503

about

Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa Vaccines for Pseudomonas aeruginosa: a long and winding road V-antigen homologs in pathogenic gram-negative bacteria Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review Modified needle-tip PcrV proteins reveal distinct phenotypes relevant to the control of type III secretion and intoxication by Pseudomonas aeruginosa A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.Multi-Functional Characteristics of the Pseudomonas aeruginosa Type III Needle-Tip Protein, PcrV; Comparison to Orthologs in other Gram-negative Bacteria Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody.Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system.Postgenomic strategies in antibacterial drug discovery.Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs.Frontier of therapeutic antibody discovery: The challenges and how to face them.The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem.High Throughput Combinatorial Formatting of PcrV Nanobodies for Efficient Potency Improvement Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.In vitro and in vivo properties of a fully human IgG1 monoclonal antibody that combats multidrug resistant Pseudomonas aeruginosa.The type III secretion system of Pseudomonas aeruginosa: infection by injection.Candida albicans airway exposure primes the lung innate immune response against Pseudomonas aeruginosa infection through innate lymphoid cell recruitment and interleukin-22-associated mucosal response Treatment options for multidrug-resistant nonfermenters.Recent developments for Pseudomonas vaccines.Will new antimicrobials overcome resistance among Gram-negatives?Novel therapeutic strategies to counter Pseudomonas aeruginosa infections.The post-antibiotic era: promising developments in the therapy of infectious diseases.New perspectives in the management of Pseudomonas aeruginosa infections.Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance.Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.Epidemiological analysis of serum anti-Pseudomonas aeruginosa PcrV titers in adults.Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.Therapeutic antibodies and infectious diseases, Tours, France, November 20-22, 2012.Antimicrobial targets localize to the extracellular vesicle-associated proteome of Pseudomonas aeruginosa grown in a biofilm.PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice.The best defense is a good (Protease) offense: How Pseudomonas aeruginosa evades mucosal immunity in the lung.

P2860

Q24612271-91847C2A-E0AD-47A3-BB62-7592E4366E6A Q26852817-6E1D96D4-6867-4BAB-8B58-0C4D11A5658C Q27008415-50EC6905-5327-460F-B2F2-5183DDFEFB2F Q27013824-B2E37621-128D-443E-88AB-4BB2F04DDB7F Q28492629-CF9B3082-28BA-42FA-A73F-3BC0524F293B Q30408273-E47DE064-4DB2-4808-8FF0-5BFA153E49C8 Q30431366-7AA5790D-0C1B-42B0-86CD-419CC0167608 Q31814859-0C2FB601-76C9-41A1-96EA-4C1B6B4D4FCE Q33622815-BBC3172B-D9C5-4311-B3CA-DAF06F8BE0A1 Q33745572-FE938242-2575-4C79-A48C-08A422D7D4DE Q34473476-2D7BB89D-9598-4A0D-BDD7-D53687BA7107 Q34527769-B7CE1E73-9B9F-48E2-AEBB-45DCDAF9F4F8 Q34711734-C8827E10-2713-4B46-8B0C-7E68358ECE8A Q34984415-DFA3EC3F-D0A8-42A6-A72D-5A62505ED994 Q36029891-53BE98FE-951F-43FC-A53E-6DECC2A265B8 Q36288672-EB5FB1C2-0F34-4A8F-8D92-6213A77D8D5E Q36487854-FD25570B-40B6-4369-9A20-B860B59D5D56 Q36613653-40F56382-CA8D-47E6-A9DA-955218709846 Q37397923-0889DA94-DE87-45C9-BD14-58CA0A377557 Q37548220-81CC0C75-2B6C-4539-A155-CAE08B9EAEFD Q37700555-C5B485FF-579A-47A1-B218-01010D28E532 Q37937369-E4E6D217-B347-4CC6-A019-D1C0A6ABE218 Q37942654-AA19689C-E59E-4134-9F08-98CE1EB4546B Q37984505-8AE9D9A9-7945-4F00-8DC0-1C698FA26962 Q38106970-BC63EA7C-A33A-429F-A43F-64B628173D6A Q38243221-38C819EE-5A83-4063-AF4E-A2AE2F53D839 Q38783043-B2AC1E6F-9D56-4D78-BB40-80C92A03D18D Q39197564-E5133500-4BC3-48E8-8791-6E2F6D588AE5 Q40267074-32A8E17E-1C30-443A-98CC-1906E1EA63F0 Q40601021-98A67781-E0E8-4BF8-A6E5-2E8ABD0E4F7D Q40860257-483EE130-79FD-4B37-9ABD-431468B29F7E Q41380601-EA5D9ABA-CA9F-4E3F-AF89-5BAB41F83A45 Q42846265-2212E2F7-C419-4F71-8ACF-F867B814C05F Q42859154-861B7301-3C3A-4030-98C9-DF47C09014EA Q43472217-80C98EFE-22F0-4A9B-970C-5874B39DDD81 Q46470522-131D98CE-B863-42B5-81A1-6F11C68AB31E

P2860

An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity.

http://www.wikidata.org/entity/Q42906503

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

An engineered human antibody f ...... potent antibacterial activity.

@en

An engineered human antibody f ...... potent antibacterial activity.

@nl

type

label

An engineered human antibody f ...... potent antibacterial activity.

@en

An engineered human antibody f ...... potent antibacterial activity.

@nl

prefLabel

An engineered human antibody f ...... potent antibacterial activity.

@en

An engineered human antibody f ...... potent antibacterial activity.

@nl

P1433

Q42906503-4F5EE51C-50C8-4DD6-92EC-B18CFEB0264C

P1476

Q42906503-8196E11F-A620-47EF-9F4C-9581CF755DC6

P2093

Q42906503-24760FE0-D78A-477F-9A3A-281B37A50D84

Q42906503-42043642-6285-4538-801F-171E1852B3FD

Q42906503-42677887-80D0-4FC1-B19B-D6C7276F1B61

Q42906503-45ACF9F1-5CD8-47DE-8525-B853D9F5D221

Q42906503-76449DF8-089F-4C78-8E68-606826DB126D

Q42906503-D45FD167-02FE-433A-959A-4EA901B1BD59

Q42906503-DF069EE6-689F-4B53-9CD6-35DCF9CE6C42

Q42906503-F8302A6E-6660-4024-8864-BEF3D9170C4E

P2860

Q42906503-1D8F4FF3-A1E3-45DB-9009-151C9B4B8E80

Q42906503-2E14010F-9414-4042-8244-9C44C2BC439B

Q42906503-3491262E-0FF7-4AEE-A5D8-325F451298FA

Q42906503-3B538F43-48B6-459A-A9E1-4F5D5E82E9DB

Q42906503-4233C589-8C12-4156-9E90-1E19F0A72D1A

Q42906503-5860A7E8-9480-4C95-B7F1-85B37C8CD71F

Q42906503-645F0A22-79F1-4831-B084-FBD55D8606C7

Q42906503-6691B99D-BF8B-456F-B9C5-4EEE76B10C0F

Q42906503-6B61759B-4F02-48F9-AAF1-ADB29AC9A376

Q42906503-6DF2B284-D9F5-4D8C-817F-ECFC20981932

P304

Q42906503-EB33CBAB-6791-445F-BA00-37F67A898559

P31

Q42906503-4669A970-D74F-4B80-A554-62FB752B0C9D

P356

Q42906503-308ED55F-9FF6-40C8-8FF6-1A7C44DA4F45

P407

Q42906503-E968DEC2-F924-4A72-9C8B-637AD85D6206

P433

Q42906503-CCF98FE6-A4A9-4DDB-81F5-0BA994B33DC9

P478

Q42906503-4F4CCAB2-0974-4430-934D-BD1F6E87BD25

P577

Q42906503-02ABD524-0924-48C9-9C8D-2A0866652847

P698

Q42906503-0F5B849A-079F-4469-8FEE-883A28C3E6A2

P921

Q42906503-4201E5D2-D27E-4789-9ADA-E7244798E463

P932

Q42906503-3CA6E1F2-CC0A-4210-ACB0-C03CCA067FCA

P356

P1433

Infection and Immunity

P1476

An engineered human antibody f ...... potent antibacterial activity.

@en

P2093

Christopher Bebbington

http://www.w3.org/2001/XMLSchema#string

David Martinez

http://www.w3.org/2001/XMLSchema#string

Geoffrey Yarranton

http://www.w3.org/2001/XMLSchema#string

Jeanine P Wiener-Kronish

http://www.w3.org/2001/XMLSchema#string

Kenneth Luehrsen

http://www.w3.org/2001/XMLSchema#string

Mark Baer

http://www.w3.org/2001/XMLSchema#string

Peter Flynn

http://www.w3.org/2001/XMLSchema#string

Teiji Sawa

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model

Lung infections associated with cystic fibrosis.

Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils.

Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo

In vitro cellular toxicity predicts Pseudomonas aeruginosa virulence in lung infections

Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.

Multiple domains are required for the toxic activity of Pseudomonas aeruginosa ExoU.

Biological effects of Pseudomonas aeruginosa type III-secreted proteins on CHO cells.

Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis

Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region

P304

1083-1090

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.00815-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19103766

http://www.w3.org/2001/XMLSchema#string

P921

P932

2643635

http://www.w3.org/2001/XMLSchema#string